$CORT

Hagens Berman sues Corcept Therapeutics for allegedly misleading investors about relacorilant's FDA prospects. Stock crashed 50% after Complete Response Letter.

Securities fraud class actions filed against PayPal, NuScale, Corcept, and Navan. Investors must file lead plaintiff motions by April 20-24, 2026.

Class action lawsuit filed against Corcept Therapeutics for allegedly making false claims about relacorilant drug's clinical strength while concealing FDA regulatory concerns.

Corcept Therapeutics faces class action lawsuit after FDA rejected relacorilant drug application, triggering 50% stock collapse and disclosure allegations.

Corcept Therapeutics faces securities class action after FDA rejected lead drug relacorilant. Stock plummeted 50.4%; lead plaintiff deadline set for April 21, 2026.

Corcept Therapeutics stock plummeted 50% after FDA rejected lead drug relacorilant. Investors allege prior misleading statements about approval likelihood.

Grabar Law Office investigates shareholder claims against $CORT, $ITGR, $KD, and $MOH for alleged disclosure failures and fiduciary breaches spanning clinical trials, sales concealment, and cost trend non-disclosure.

Rosen Law Firm files securities class action against Ardent Health for alleged misrepresentations in accounts receivable and insurance reserves. March 9 deadline for lead plaintiff claims.

Law firm files securities lawsuit against $CORT alleging false statements about FDA interactions regarding relacorilant drug approval prospects.

Rosen Law Firm filed securities class action against Oracle, alleging materially false statements about AI infrastructure strategy and undisclosed capital expenditures. Affected investors urged to consult legal counsel before deadline.

Rosen Law Firm sues Corcept Therapeutics for allegedly making misleading statements about clinical trial data and FDA approval prospects for its relacorilant drug candidate.

Corcept faces securities lawsuit over misleading relacorilant claims. FDA rejected the drug, triggering 50% stock decline and $3.6B market cap loss.

Corcept Therapeutics faces securities lawsuit alleging misrepresentation of relacorilant clinical data and FDA approval prospects, while withholding known regulatory risks from investors.

Portnoy Law Firm sues Corcept Therapeutics over alleged misrepresentations about drug candidate relacorilant, following FDA rejection that caused stock to plummet 50%.

Corcept faces securities lawsuit after FDA rejected its drug candidate, causing 50% stock drop. Investors must apply by April 21 for class action lead plaintiff status.

Corcept Therapeutics faces securities lawsuit alleging it misrepresented relacorilant's FDA approval prospects, causing stock to plunge 50% after regulatory rejection.

uniQure faces securities fraud lawsuit after FDA rejected its drug candidate AMT-130, causing a 49% stock plunge. Plaintiffs allege the company failed to disclose material information to investors.

Corcept Therapeutics faces securities fraud lawsuit for failing to disclose FDA setback on relacorilant drug, causing 50% stock decline.

Law firm files securities fraud lawsuit against BellRing after 52% stock plunge, alleging failure to disclose inventory and supply chain issues.

Corcept Therapeutics faces class action lawsuit for allegedly misleading statements about relacorilant's clinical evidence. FDA rejected the drug application, causing stock to plummet 50%.